<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

 

Glioblastoma (GBM) PDX Models
A Champions Model Cohort

A robust cohort of rare and meticulously curated Glioblastoma Patient-derived xenograft models directly established from primary, late-stage, and pre-treated patient tumors to support your glioblastoma cancer drug development research.

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

An Advanced Cohort of Glioblastoma PDX Models

Champions Oncology has established an advanced cohort of Glioblastoma patient-derived xenograft (PDX) models, providing a comprehensive platform for glioblastoma research. Our glioblastoma malignancy bank includes 30* PDX  models derived from patient samples, preserving their original molecular and clinical characteristics while minimizing genetic drift commonly seen in passaged models. Additional details on these models are available through Champions’ Model Select®.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Glioblastoma PDX Models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest bank of glioblastoma models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like EGFR antibody-drug conjugate, BTK inhibitors, Temozolomide, Bevacizumab, and more.